Home » Stocks » Translate Bio

Translate Bio, Inc. (TBIO)

Stock Price: $13.52 USD -0.51 (-3.64%)
Updated Oct 26, 2020 12:46 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.00B
Revenue (ttm) 26.13M
Net Income (ttm) -102.83M
Shares Out 74.24M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE 29.67
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $13.52
Previous Close $14.03
Change ($) -0.51
Change (%) -3.64%
Day's Open 13.76
Day's Range 13.43 - 14.07
Day's Volume 277,787
52-Week Range 6.80 - 28.09

More Stats

Market Cap 1.00B
Enterprise Value 722.98M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 74.24M
Float 63.72M
EPS (basic) -1.74
EPS (diluted) -1.76
FCF / Share -1.58
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 11.09M
Short Ratio 9.69
Short % of Float 17.41%
Beta 0.30
PE Ratio n/a
Forward PE 29.67
P/FCF Ratio n/a
PS Ratio 38.42
PB Ratio 3.96
Revenue 26.13M
Operating Income -104.80M
Net Income -102.83M
Free Cash Flow -98.40M
Net Cash 280.80M
Net Cash / Share 3.78
Gross Margin -148.79%
Operating Margin -401.08%
Profit Margin -393.60%
FCF Margin -376.58%
ROA -16.01%
ROE -53.13%
ROIC -115.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 9
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(121.89% upside)
Current: $13.52
Target: 30.00
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth449.58%---
Gross Profit7.801.42--
Operating Income-116-104-79.25-26.80
Net Income-113-97.40-66.44-26.70
Shares Outstanding51.4526.957.761.51
Earnings Per Share-2.20-3.64-8.66-18.14
Operating Cash Flow-82.16-22.13-50.79-23.72
Capital Expenditures-3.54-6.58-2.77-0.86
Free Cash Flow-85.70-28.71-53.56-24.58
Cash & Equivalents19014560.0271.75
Total Debt12.61---
Net Cash / Debt17714560.0271.75
Book Value154125-93.52-38.59
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Translate Bio, Inc.
Country United States
Employees 93
CEO Ronald C. Renaud

Stock Information

Ticker Symbol TBIO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TBIO
IPO Date June 28, 2018


Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.